A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Inclusion Criteria: * Willing and able to provide informed consent * Diagnosis of mild cognitive impairment (MCI) due to probable AD or of mild AD * MMSE range: 20 to 28 * Evidence of amyloid pathology by amyloid PET scan * Participants may be taking medications for AD, provided that the dose of these medications has been stable for \>3 months * Proficiency in Dutch and adequate visual and auditory abilities to be able to perform all aspects of the cognitive and functional tests * Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments. Exclusion Criteria: * Evidence of neurodegenerative disease other than AD * Inability for any reason to undergo PET and fMRI scans (including notably: history of allergic reaction of any severity to 11C-PiB injection; pacemaker, vascular stent or stent graft) * Psychiatric disorder that would compromise ability to comply with study requirements * Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy * Recent (\<90 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition * Participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study * Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements * Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy * Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial * Any factor deemed by the investigator to be likely to interfere with study conduction